469 filings
Page 6 of 24
SC 13G/A
30e5rjd 9dmiw117vt
13 Feb 23
Replimune / Omega Fund IV ownership change
4:49pm
8-K
uu3 t0tswft
9 Feb 23
Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update
8:15am
SC 13G
p5vwis3zuhyqhkbf
3 Feb 23
Replimune / BlackRock ownership change
12:10pm
8-K
gh4xkz
4 Jan 23
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
9:15am
4
5lqbf 3cjucj9
13 Dec 22
Replimune / Pamela Esposito ownership change
8:01pm
8-K
zukirdc2j bzh8qs
12 Dec 22
Replimune Announces Proposed Public Offering
5:00pm
424B5
50hm7gpwmm3vt 3f
12 Dec 22
Prospectus supplement for primary offering
6:03am
424B5
ive1tte
7 Dec 22
Prospectus supplement for primary offering
4:58pm
8-K
50g66 5y0
7 Dec 22
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
7:15am
SC 13D/A
h5tmsm23b narip7p5
6 Dec 22
Replimune / Atlas Venture Fund X ownership change
5:00pm
4
ujs slqeinfsbobw
5 Dec 22
Replimune / Konstantinos Xynos ownership change
8:01pm
3
532zodpbi x4algt9xv1
5 Dec 22
Replimune / Konstantinos Xynos ownership change
8:00pm
SC 13G/A
org644lg ow9zzvx
18 Nov 22
Replimune / Redmile ownership change
5:17pm
8-K
5qnzg9 lwj5h0i9t
3 Nov 22
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
8:11am
8-K
hwy 9qx1yybhoiia
7 Oct 22
Entry into a Material Definitive Agreement
8:20am
SC 13D/A
rsprjmz vcr0nfkv
14 Sep 22
Replimune / Atlas Venture Fund X ownership change
5:06pm
8-K
d5qcaz51r11la f9h
8 Sep 22
Submission of Matters to a Vote of Security Holders
4:10pm